Dupixent Lawsuit Lawyer in Pennsylvania and New Jersey

Name: Dupixent Lawsuit
Brand: Kwartler Manus
Rating: 4.9 (536 reviews)

You trusted this medication to help you heal. Now, alarming research is raising serious questions about whether that same drug may have contributed to a rare and dangerous cancer. If you received Dupixent injections and were later diagnosed with cutaneous T-cell lymphoma, you may have legal rights, and Kwartler Manus is ready to fight for you.

Our Attorneys Are Actively Investigating Dupixent CTCL Claims, and We Want to Hear Your Story

Kwartler Manus is a trial-ready personal injury and mass tort firm representing clients throughout Pennsylvania and New Jersey. With more than 250 jury trials, $100 million recovered, and a team built for high-stakes complex litigation, we pursue full accountability when manufacturers put patients at risk.

What Is Dupixent (Dupilumab)?

Dupixent (dupilumab) is a prescription biologic medication manufactured by Sanofi and Regeneron. It is administered by injection and works as an interleukin inhibitor, blocking the IL-4 and IL-13 protein pathways that drive inflammation.

Because it suppresses certain immune system responses, Dupixent has been approved by the FDA to treat a wide range of chronic inflammatory conditions.

The FDA has approved Dupixent to treat nine conditions, including:

Moderate-to-severe atopic dermatitis (eczema)
Uncontrolled moderate-to-severe asthma
Chronic obstructive pulmonary disease (COPD) with high blood eosinophils
Chronic rhinosinusitis with nasal polyps (CRSwNP)
Eosinophilic esophagitis (EOE)
Chronic spontaneous urticaria (CSU)
Bullous pemphigoid (BP)
Prurigo nodularis (PN)
Allergic fungal rhinosinusitis (AFRS)

Dupixent was initially approved in March 2017 to treat adult patients with atopic dermatitis and has since expanded to multiple additional conditions and age groups, including children as young as one year old for certain indications. It is one of the most widely prescribed biologics in the United States.

That immune-suppressing mechanism is also why Dupixent has become the subject of serious litigation. By blocking key inflammatory pathways, the drug may impair the body's ability to detect and respond to abnormal T-cell activity, including a rare cancer called cutaneous T-cell lymphoma (CTCL).

Here are some key facts about CTCL:

It is a rare type of non-Hodgkin lymphoma that develops when T-cells become malignant and accumulate in the skin
It can progress to affect the lymph nodes, bloodstream, and internal organs
In its early stages, CTCL can look nearly identical to atopic dermatitis or eczema -- the same condition Dupixent is prescribed to treat
That resemblance can cause significant delays in diagnosis, particularly in patients already on Dupixent
By the time CTCL is correctly identified, the disease may have advanced

A Deeper Look at the Link Between Dupixent and Cutaneous T-Cell Lymphoma

Multiple peer-reviewed studies have identified a possible association between Dupixent use and CTCL, and the FDA is actively investigating the connection:

A 2024 retrospective cohort study published in the Journal of the American Academy of Dermatology found that atopic dermatitis patients taking Dupixent were approximately four times more likely to develop CTCL than those with eczema who were not prescribed the drug
A separate 2024 study put that figure even higher, finding Dupixent patients more than 4.5 times as likely to receive a CTCL diagnosis compared to non-Dupixent eczema patients
Research published in 2025 examined 31 patients with atopic dermatitis who were given Dupixent; 27 of those patients subsequently developed a form of CTCL
As of 2026, the FDA has listed Dupixent as a potential signal of serious risk in its Adverse Event Reporting System and is evaluating whether regulatory action is warranted

Dupixent suppresses certain inflammatory immune pathways, potentially impairing the body's ability to detect abnormal T-cell activity. Researchers are investigating whether Dupixent accelerates or unmasks cutaneous T-cell lymphoma (CTCL) or contributes to its development.

Notably, CTCL diagnoses in Dupixent users are occurring at younger ages than expected in the general eczema population. While direct causation is not yet established, this growing body of evidence has led the FDA to list Dupixent as a potential serious risk in its adverse event reporting system.

This is precisely what failure-to-warn lawsuits are built for: when manufacturers market a drug while suppressing or ignoring safety signals that patients have a right to know about.

Why Is There a Dupixent Lawsuit?

The Dupixent lawsuit is a growing body of individual pharmaceutical liability claims filed against Dupixent's manufacturers, Sanofi, Regeneron, and Genzyme, by patients who were prescribed the drug and later diagnosed with CTCL.

Under the legal theory of failure to warn, plaintiffs allege that the manufacturers knew or should have known of a possible association between Dupixent use and CTCL, yet failed to adequately disclose that risk to patients and prescribing physicians.

Plaintiffs allege that Sanofi, Regeneron, and Genzyme:

Failed to warn patients and physicians of the possible connection between Dupixent and CTCL
Failed to conduct adequate testing and post-market monitoring to understand Dupixent's long-term health effects
Improperly marketed Dupixent without disclosing serious safety risks
Downplayed or concealed evidence linking the drug to CTCL diagnoses
Failed to update prescribing information as scientific evidence of a possible association mounted

Failure to warn is a recognized product liability claim under both Pennsylvania law and New Jersey law, imposing a duty on drug manufacturers to provide adequate warnings of known or reasonably foreseeable risks.

2026 Dupixent Lawsuit Updates

June 11, 2026

A Tennessee patient filed a lawsuit against Sanofi and Regeneron after being prescribed Dupixent for atopic dermatitis from January 2025 to September 2025 and subsequently receiving a CTCL diagnosis
The complaint alleges that Dupixent contributed to his lymphoma and that he was never warned of this risk

June 5, 2026

The Judicial Panel on Multidistrict Litigation (JPML) formally approved the creation of a federal multidistrict litigation for Dupixent CTCL claims
The MDL, designated MDL No. 3180 (In re: Dupixent (Dupilumab) Products Liability Litigation), has been centralized in the United States District Court for the District of New Jersey
The Honorable Zahid N. Quraishi will oversee the MDL

April 16, 2026

Attorneys submitted a motion to the JPML to create a centralized Dupixent MDL for patients alleging their CTCL was induced or unmasked by the drug
The JPML held a hearing on May 28, 2026, before granting the motion

February 13, 2026

Attorneys representing 15 plaintiffs filed a motion with the JPML to consolidate Dupixent lawsuits into a single multidistrict litigation
They cite an increasing number of patients who developed CTCL following Dupixent treatment

Who Is Eligible to File a Dupixent Lawsuit?

You may qualify to pursue a Dupixent claim if you fall into one or more of the following categories:

You received Dupixent injections and were subsequently diagnosed with cutaneous T-cell lymphoma (CTCL)
You are the spouse of a Dupixent patient diagnosed with CTCL and are pursuing a loss of consortium claim
You are a surviving spouse or eligible family member of a patient who used Dupixent, developed CTCL, and passed away, and you are pursuing a wrongful death claim

The JPML has also left open the possibility that patients who developed other types of T-cell lymphoma following Dupixent use may be eligible to join the MDL as the litigation develops and additional evidence is evaluated.

Do not assume you are ineligible without speaking to an attorney. Call Kwartler Manus at (267) 457-4132 for a free, confidential case evaluation.

Dupixent MDL vs. Class Action: What Is the Difference?

The Dupixent litigation is structured as a multidistrict litigation (MDL), not a class action lawsuit. This distinction matters significantly to individual plaintiffs.

In a class action, all plaintiffs are grouped together and typically receive a uniform settlement amount. An MDL works differently. Each plaintiff retains their individual case, but certain pretrial proceedings are centralized to improve efficiency and reduce duplicative costs.

That structure gives patients the best of both worlds:

Shared discovery resources, so plaintiffs are not individually bearing the cost of deposing the same experts
Coordinated pretrial proceedings that move the litigation forward faster
Individual case evaluation at the time of trial or settlement, based on each plaintiff's specific diagnosis, medical expenses, lost income, and personal impact
The right to individual compensation, not a pooled payout divided among all claimants

Katie Koelsch writing down client's statement

What Damages Can Dupixent Victims Recover?

Patients who took Dupixent and developed CTCL may be entitled to significant financial compensation.

Recoverable damages in a pharmaceutical mass tort case typically include:

Medical expenses: Past and future costs of diagnosing and treating CTCL, including biopsies, chemotherapy, radiation, immunotherapy, and related care
Lost income and earning capacity: Wages lost during treatment, and any long-term reduction in earning potential caused by the illness
Pain and suffering: Physical pain, emotional distress, and the impact of a cancer diagnosis on quality of life
Loss of enjoyment of life: Compensation for the ways CTCL has diminished the plaintiff's ability to engage in activities and relationships they previously valued
Wrongful death damages: Recoverable by eligible surviving family members, including funeral and burial expenses, loss of financial support, loss of companionship, and mental anguish

Steps to Take If You Were Diagnosed With CTCL After Taking Dupixent

1. Seek and document your medical care

Continue all prescribed treatment for your CTCL diagnosis
Keep records of every appointment, prescription, procedure, and diagnosis

2. Preserve your Dupixent prescription records

Gather any records confirming your Dupixent prescriptions, the dosing history, and the dates of your injections
Pharmacy records, insurance claims, and physician notes are all valuable

3. Do not accept any settlement from the manufacturer without legal counsel

Pharmaceutical companies may reach out early with offers that appear generous but significantly undervalue your claim
Speak to an attorney before signing anything

4. Contact Kwartler Manus

The sooner we begin building your case, the stronger it will be
Call (267) 457-4132 for a free and confidential consultation with our mass tort team

Why Choose Kwartler Manus for Your Dupixent Lawsuit in Pennsylvania and New Jersey

Mass tort litigation against major pharmaceutical companies is complex. These corporations have deep resources and experienced legal teams working to minimize your recovery from day one. You need attorneys who will fight just as hard, and just as strategically.

At Kwartler Manus, we do not wait for manufacturers to do the right thing. We file early, push hard, and prepare every case as if it is going to trial. Partner Pamela Playo Lin brings more than 13 years of experience in complex mass-tort and catastrophic-injury litigation, including co-counsel on the landmark $227 million Salvation Army Market Street Collapse settlement. She has litigated multi-district cases involving devastating injuries and knows how to position pharmaceutical claims for maximum recovery.

Our firm credentials include the following:

$100 million+ recovered for clients across Pennsylvania and New Jersey
250+ jury trials; 2,500+ total cases
4.9-star rating based on 498 client reviews
Trial-first approach: we prepare every case for court from day one
Former insurance defense attorneys on staff who know exactly how the other side evaluates claims

We handle Dupixent CTCL claims on a contingency-fee basis, meaning you pay nothing unless we recover compensation for you; there is no risk in making the call.

Dupixent Lawsuit FAQs

How long do I have to file a Dupixent lawsuit?

The deadline to file depends on the statute of limitations in your state.

In Pennsylvania, the statute of limitations for personal injury claims is generally two years from the date of injury or discovery, under 42 Pa. C.S. § 5524. In New Jersey, the standard limitations period is also two years, under N.J.S.A. 2A:14-2.

However, the discovery rule may extend this deadline depending on when you knew, or reasonably should have known, that your CTCL was connected to your Dupixent use.

Exceptions may also apply to wrongful death claims. The safest course is to contact an attorney as soon as possible so you do not lose your right to recover.

Is this a class action lawsuit?

No. The Dupixent litigation is structured as a multidistrict litigation (MDL), not a class action. Each plaintiff maintains their individual case and is entitled to compensation based on their own damages, not a shared pool. MDL No. 3180 was approved by the Judicial Panel on Multidistrict Litigation on June 5, 2026, and is centralized in the District of New Jersey.

What is the legal process for a Dupixent claim?

The process typically begins with a free consultation and a review of your medical records and Dupixent prescription history. If you qualify, your attorney files a complaint. Your case then enters the MDL's pretrial phase, where discovery and expert evidence are developed alongside those of other plaintiffs. From there, cases may proceed to individual trials or resolve through negotiated settlements. Our team will guide you through every step.

What will it cost me to hire Kwartler Manus for a Dupixent claim?

Nothing unless we win. Kwartler Manus handles Dupixent mass-tort claims on a contingency-fee basis. There are no upfront costs and no legal fees owed unless we recover compensation on your behalf.

Can I still file if I am not sure whether my CTCL was caused by Dupixent?

Yes. Many plaintiffs in drug liability cases do not have certainty about causation at the time they file. That is precisely what litigation is designed to establish. If you took Dupixent and were later diagnosed with CTCL, you may have a viable claim even if your treating physicians have not directly attributed the diagnosis to the drug.

Kwartler Manus Is Ready to Fight for Dupixent Victims in Pennsylvania and New Jersey

You took a medication you were told was safe for your condition, but you were never warned that it might increase your risk of developing cancer. That is not acceptable, and it is not something you should face alone.

Kwartler Manus is a trial-ready personal injury and mass tort firm with a long record of holding corporations accountable for the harm they cause. Our attorneys are relentless, our preparation is thorough, and our commitment to our clients does not waver. We have recovered over $100 million for injured clients across Pennsylvania and New Jersey, and we are ready to fight for you.

If you or a loved one received Dupixent and were diagnosed with cutaneous T-cell lymphoma, contact Kwartler Manus today for a free and confidential consultation. Do not wait. The statute of limitations is running, and the sooner we act, the stronger your case will be.

Call (267) 457-4132 now. Speak with an attorney in under 30 seconds. No fees unless we win.

Disclaimer: The information on this page is provided for general educational purposes only and does not constitute legal advice. Every case is different. Past results do not guarantee future outcomes. Contact an attorney to discuss the specific facts of your situation.